

## REFERENCES

1. Centers for Disease Control and Prevention. Tetanus surveillance-United States, 1998-2000. *MMWR Surveill Summ.* 2003;52:1-8.
2. Centers for Disease Control and Prevention. Childcare and School Vaccination Requirements, 2007-2008. Available at: <http://www2.cdc.gov/nip/school-surv/immunizationrqmts.htm>. Accessed October 15, 2009.
3. Centers for Disease Control and Prevention. Diphtheria, tetanus, and pertussis. Recommendations for vaccine use and other preventive measures. Recommendations of the Immunization Practices Advisory Committee (ACIP). *MMWR Recomm Report.* 1991;40(RR10):1-28.
4. Centers for Disease Control and Prevention. National, state, and local vaccination coverage among children aged 19-35 months-United States, 2008. *MMWR Morb Mortal Wkly Rep.* 2009;58:921-926.
5. Centers for Disease Control and Prevention. Vaccination coverage estimates from the National Health Interview Survey: United States, 2008. Available at: [http://www.cdc.gov/nchs/data/hestat/vaccine\\_coverage.pdf](http://www.cdc.gov/nchs/data/hestat/vaccine_coverage.pdf). Accessed October 15, 2009.
6. McQuillan GM, Kruszon-Moran D, Deforest A, et al. Serologic immunity to diphtheria and tetanus in the United States. *Ann Intern Med.* 2002;136:660-666.
7. Brand DA, Acampora D, Gottlieb LD, et al. Adequacy of antitetanus prophylaxis in six hospital emergency rooms. *N Engl J Med.* 1983;309:636-640.
8. Talan DA, Abrahamian FM, Moran GJ, et al. Tetanus immunity and physician compliance with tetanus prophylaxis practices among emergency department patients presenting with wounds. *Ann Emerg Med.* 2004;43:305-314.
9. Thorley JD, Holmes RK, Sanford JP. Tetanus and diphtheria anti-toxin levels following a hospital-based adult immunization program. *Am J Epidemiol.* 1975;101:438-443.
10. Centers for Disease Control and Prevention. Summary of notifiable diseases-United States, 2004. *MMWR Morb Mortal Wkly Rep.* 2006;53:1-79.
11. Kretsinger K, Broder KR, Cortese MM, et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recommend Report.* 2006;55(RR-17):1-37.
12. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. *Pediatr Infect Dis J.* 2005;24:S58-S61.
13. Cortese MM, Baughman AL, Brown K, Srivastava P. A "new age" in pertussis prevention: new opportunities through adult vaccination. *Am J Prev Med.* 2007;32:177-185.
14. Cherry JD. The science and fiction of the "resurgence" of pertussis. *Pediatrics.* 2003;112:405-406.
15. Lambert HJ. Epidemiology of a small pertussis outbreak in Kent County, Michigan. *Pub Health Rep.* 1965;80:365-369.
16. Jenkinson D. Duration of effectiveness of pertussis vaccine. Evidence from a 10-year community study. *BMJ.* 1988;296:612-614.
17. Olin P, Gustafsson L, Barreto L, et al. Declining pertussis incidence in Sweden follow the introduction of acellular pertussis vaccine. *Vaccine.* 2003;21:2015-2021.
18. Bass JW, Wtitler RR. Return of epidemic pertussis in the United States. *Pediatr Infect Dis J.* 1994;13:343-345.
19. Bass JW, Stephenson SR. The return of pertussis. *Pediatr Infect Dis.* 1987;6:141-144.
20. Black S. Epidemiology of pertussis. *Pediatr Infect Dis J.* 1997;16:S85-S89.
21. Centers for Disease Control and Prevention. School-associated pertussis outbreak-Yavapai County, Arizona, September 2002-February 2003. *MMWR Morb Mortal Wkly Rep.* 2004;53:216-219.
22. Centers for Disease Control and Prevention. Pertussis outbreak-Vermont, 1996. *MMWR Morb Mortal Wkly Rep.* 1997;46:822-826.
23. Centers for Disease Control and Prevention. Pertussis outbreaks-Massachusetts and Maryland, 1992. *MMWR Morb Mortal Wkly Rep.* 1993;42:197-200.
24. Craig AS, Wright SW, Edwards KM, et al. Outbreak of pertussis on a college campus. *Am J Med.* 2007;120:364-368.
25. Situr MJ, Cappozzo DL, Warshauer DM, et al. A countywide outbreak of pertussis: initial transmission in a high school weight room with subsequent substantial impact on adolescents and adults. *Arch Pediatr Adolesc Med.* 2008;162:79-85.
26. Schafer S, Gillette H, Hedberg K, Cieslak P. A community-wide pertussis outbreak: an argument for universal booster vaccination. *Arch Intern Med.* 2006;166:1317-1321.
27. Centers for Disease Control and Prevention. Pertussis outbreak among adults at an oil refinery-Illinois, August-October 2002. *MMWR Morb Mortal Wkly Rep.* 2003;52:1-4.
28. Centers for Disease Control and Prevention. Pertussis-United States, 2001-2003. *MMWR Morb Mortal Wkly Rep.* 2005;54:1283-1286.
29. Bisgard KM, Pascual FB, Ehresmann KR, et al. Infant pertussis: who was the source? *Pediatr Infect Dis J.* 2004;23:985-999.
30. Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recommend Report.* 2006;55(RR-3):1-34.
31. Food and Drug Administration. June 10, 2005 Approval letter-ADACEL. Available at: <http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm142777.htm>. Accessed November 5, 2009.
32. Food and Drug Administration. May 3, 2005 Approval letter-BOOSTRIX. Available at: <http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172933.htm>. Accessed November 5, 2009.
33. Long SS. ACIP votes to recommend adolescent pertussis booster: CDC, Academy policy likely to parallel ACIP recommendation. *AAP News.* 2005;26:1-16.
34. Food and Drug Administration. Product information [package insert]. Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed ADA-CEL. Sanofi pasteur. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; 2009. Available at: <http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142764.pdf>. Accessed January 24, 2010.
35. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices recommends adult vaccination with new tetanus, diphtheria, and pertussis vaccine (Tdap). Available at: <http://www.cdc.gov/media/pressrel/r051109.htm>. Accessed November 6, 2009.
36. Food and Drug Administration. Product information [package insert]. Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed BOOSTIX. GlaxoSmithKline Biologicals. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; 2008. Available at: <http://www.fda.gov/downloads/BiologicsBloodVaccines/UCM152842.pdf>. Accessed Jan 24, 2010.
37. Pichicerio ME, Rennels MB, Edwards KM, et al. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. *JAMA.* 2005;293:3003-3011.
38. Holdsworth RJ, Irving AD, Cuschieri A. Postsplenectomy sepsis and its mortality rate: actual versus perceived risks. *Br J Surg.* 1991;78:1031-1038.
39. Schwartz PE, Sterioff S, Mucha P, et al. Postsplenectomy sepsis and mortality among adults. *JAMA.* 1982;248:2279-2283.
40. Ejstrup P, Kristensen B, Hansen JB, et al. Risks and patterns of bacteraemia after splenectomy: a population-based study. *Scand J Infect Dis.* 2000;32:521-525.
41. Schilling RF. Estimating the risk for sepsis after splenectomy in hereditary spherocytosis. *Ann Intern Med.* 1995;122:187-188.
42. Lynch AM, Kapila R. Overwhelming postsplenectomy infection. *Infect Dis Clin North Am.* 1996;10:693-707.
43. Ellison EC, Babri PJ. Complications of splenectomy. *Surg Clin North Am.* 1983;63:1313-1330.
44. Cullingford GL, Watkin DN, Watts AD, Mallon DF. Severe late postsplenectomy infection. *Br J Surg.* 1991;78:716-721.

45. Horan M, Colebatch JH. Relation between splenectomy and subsequent infection: a clinical study. *Arch Dis Child*. 1962;37:398-414.
46. Waghorn DJ. Overwhelming infection in asplenic patients: current best practice preventive measures are not being followed. *J Clin Pathol*. 2001;54:214-218.
47. Singer DB. Postsplenectomy sepsis. *Perspect Pediatr Pathol*. 1973;1:285-311.
48. Aavitsland P, Froholm LO, Hoiby EA, Lystad A. Risk of pneumococcal disease in individuals without a spleen. *Lancet*. 1994;344:1504.
49. Green JB, Shackford SR, Sise MJ, et al. Late septic complications in adults following splenectomy for trauma: a prospective analysis of 144 patients. *J Trauma*. 1986;26:999-1004.
50. Styr B. Infection associated with asplenia: risks, mechanisms, and prevention. *Am J Med*. 1990;88:33N-42N.
51. Zarrabi MH, Rosner F. Serious infections in adults following splenectomy for trauma. *Arch Intern Med*. 1984;144:1421-1424.
52. Krivit W. Overwhelming postsplenectomy infection. *Am J Hematol*. 1977;2:193-201.
53. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep*. 1997;46(RR8):1-24.
54. Centers for Disease Control and Prevention. Recommended adult immunization schedule-United States, 2010. *MMWR*. 2010;59(01):1-4.
55. Centers for Disease Control and Prevention. Recommended adult immunization schedule-United States, 2009. *MMWR*. 2009;57(53):Q1-Q4.
56. De Roux A, Schmoele-Thoma B, Siber GR, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. *Clin Infect Dis*. 2008;46:1015-1023.
57. Dransfield MT, Nahm MH, Han MK, et al. Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2009;180:499-505.
58. Miernyk KM, Butler JC, Bulkow LR, et al. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in Alaska native adults 55-70 years of age. *Clin Infect Dis*. 2009;49:241-248.
59. Centers for Disease Control and Prevention. Recommended immunization schedules for persons 0 through 18 years-United States, 2010. *MMWR*. 2010;58(51&52):1-4.
60. Musher DM, Rueda AM, Nahm MH, et al. Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. *J Infect Dis*. 2008;198:1019-1027.
61. Kumar D, Chen MH, Wong G, et al. A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients. *Clin Infect Dis*. 2008;147:885-892.
62. Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep*. 2005;54:1-21.
63. Popovic T, Schuchat A, Harrison LH, Reingold AL. The changing epidemiology of meningococcal disease in the United States, 1992-1996. *J Infect Dis*. 1999;180:1894-1901.
64. Balmer P, Falconer M, McDonald P, et al. Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals. *Infect Immun*. 2004;72:332-337.
65. Pichichero M, Casey J, Blatter M, et al. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children. *Pediatr Infect Dis J*. 2005;24:57-62.
66. Jackson LA, Jacobson RM, Reisinger KS, et al. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. *Pediatr Infect Dis J*. 2009;28:86-91.
67. Vu DM, Welsch JA, Zuno-Mitchell P, et al. Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine. *J Infect Dis*. 2006;193:821-828.
68. Keyserling H, Papa T, Koranyi K, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. *Arch Pediatr Adolesc Med*. 2005;159:907-913.
69. Cimaz R, Mensi C, D'Angelo E et al. Safety and immunogenicity of a conjugate vaccine against *Haemophilus influenzae* type b in splenectomized and non-splenectomized patients with Cooley anemia. *J Infect Dis*. 2001;183:1819-1821.
70. Ambrosino DM, Lee MY, Chen D, Shamberger RC. Response to *Haemophilus influenzae* type B conjugate vaccine in children undergoing splenectomy. *J Pediatr Surg*. 1992;27:1045-1047.
71. Kristensen K. Antibody response to *Haemophilus influenzae* b polysaccharide tetanus toxoid conjugate vaccines in splenectomized children and adolescents. *Scand J Infect Dis*. 1992;24:629-632.
72. Shatz DV, Schinsky MF, Pais LB, et al. Immune responses of splenectomized trauma patients to the 23-valent pneumococcal polysaccharide vaccine at 1 versus 7 versus 14 days after splenectomy. *J Trauma*. 1998;44:760-766.
73. Shatz DV, Romero-Steiner S, Elie CM, et al. Antibody responses in post-splenectomy trauma patients receiving the 23-valent pneumococcal polysaccharide vaccine at 14 versus 28 days postoperatively. *J Trauma*. 2002;53:1037-1042.
74. Centers for Disease Control and Prevention. Updated recommendations from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease. *MMWR Morb Mortal Wkly Rep*. 2009;58:1042-1043.
75. Kyaw MH, Holmes EM, Chalmers J, et al. A survey of vaccine coverage and antibiotic prophylaxis in splenectomised patients in Scotland. *J Clin Pathol*. 2002;55:472-474.
76. Meerveld-Eggink A, de Weerd O, Rijkers GT, et al. Vaccination coverage and awareness of infectious risks in patients with absent or dysfunctional spleen in the Netherlands. *Vaccine*. 2008;26:6975-6979.
77. Bruni L, Bayas JM, Vilella A, Conesa A. Vaccination coverage in adults undergoing splenectomy: evaluation of hospital vaccination policies. *Epidemiol Infect*. 2006;134:837-844.
78. Musher DM, Ceasar H, Kojic EM, et al. Administration of protein-conjugate pneumococcal vaccine to patients who have invasive disease after splenectomy despite their having received 23-valent pneumococcal polysaccharide vaccine. *J Infect Dis*. 2005;191:1063-1067.
79. Brivet F, Herer B, Fremaux A, et al. Fatal post-splenectomy pneumococcal sepsis despite pneumococcal vaccine and penicillin prophylaxis. *Lancet*. 1984;2:356-357.
80. Schlaeffer F, Rosenheck S, Baumgarten-Kleiner A et al. Pneumococcal infections among immunized and splenectomised patients in Israel. *J Infect*. 1985;10:38-42.
81. Schutze GE, Mason EO, Barson VJ, et al. Invasive pneumococcal infections in children with asplenia. *Pediatr Infect Dis J*. 2002;21:278-282.
82. Daniels D, Grytdal S, Wasley A; Centers for Disease Control and Prevention (CDC). Surveillance for acute viral hepatitis-2007. *MMWR Surveill Summ*. 2009;58(SS-03):1-27.
83. Colvin HM, Mitchell AE, eds. Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. Washington, DC: The National Academies Press; 2010. Uncorrected proof available at: [http://books.nap.edu/openbook.php?record\\_id=12793&page=R1](http://books.nap.edu/openbook.php?record_id=12793&page=R1). Accessed February 19, 2010.
84. Thompson ND, Perz JF, Moorman AC, Holmberg SD. Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998-2008. *Ann Intern Med*. 2009;150:33-39.
85. Williams IT, Perz JF, Bell BP. Viral hepatitis transmission in ambulatory health care settings. *Clin Infect Dis*. 2004;38:1592-1598.

86. Centers for Disease Control and Prevention. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP). *MMWR Recomm Rep*. 1991;40(RR-13):1-19.
87. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States—recommendations of the Advisory Committee on Immunization Practices (ACIP). Part II: immunization of adults. *MMWR Recomm Rep*. 2006;55(RR-16):1-33.
88. Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. Part 1: immunization of infants, children, and adolescents. *MMWR Recomm Rep*. 2005;54(No. RR-16).
89. Centers for Disease Control and Prevention. Hepatitis B vaccination coverage among adults—United States, 2004. *MMWR Morb Mortal Wkly Rep*. 2004;55(18):509-511.
90. Simard EP, Miller JT, George PA, et al. Hepatitis B vaccination coverage levels among healthcare workers in the United States, 2002-2003. *Infect Control Hosp Epidemiol*. 2007;28:783-790.
91. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. *N Engl J Med*. 1998;338:286-290.
92. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep*. 2006;55:1-23.
93. Van Damme P, Thoelen S, Cramm M, et al. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. *J Med Virol*. 1994;44:446-451.
94. McMahon BJ, Williams J, Bulkow L, et al. Immunogenicity of an inactivated hepatitis A vaccine in Alaska Native children and Native and non-Native adults. *J Infect Dis*. 1995;171:676-679.
95. Innis BL, Snithbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. *JAMA*. 1994;271:1328-1334.
96. Werzberger A, Mensch B, Kuter B, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. *N Engl J Med*. 1992;327:453-457.
97. Keffe EB, Iwarson S, McMahon BJ, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. *Hepatology*. 1998;27:881-886.
98. Smallwood GA, Coloura CT, Martinez E, et al. Can patients awaiting liver transplantation elicit an immune response to hepatitis A vaccine. *Transplant Proc*. 2002;34:3289-3290.
99. Dumot JA, Barnes DS, Younossi Z, et al. Immunogenicity of hepatitis A vaccine in decompensated liver disease. *Am J Gastroenterol*. 1999;94:1601-1604.
100. Arguedas MR, Johnson A, Eloubeidi MA, Fallon MB. Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patients. *Hepatology*. 2001;32:28-31.
101. Andre FE. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. *Am J Med*. 1989;87[suppl 3A]:S14-S20.
102. Zajac BA, West DJ, McAleer WJ, Scolnick EM. Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. *J Infect*. 1986;13(suppl A):39-45.
103. Averhoff F, Mahoney F, Coleman P, et al. Immunogenicity of hepatitis B vaccines: implications for persons at occupational risk for hepatitis B virus infection. *Am J Prev Med*. 1998;15:1-8.
104. Zanetti AR, Mariano A, Romano L, et al. Long-term immunogenicity of hepatitis B vaccinations and policy for booster: an Italian multicenter study. *Lancet*. 2005;366:1379-1384.
105. McMahon BJ, Bruden DL, Petersen KM, et al. Antibody levels and protection against hepatitis B vaccination: results of a 15-year follow-up. *Ann Intern Med*. 2005;142:333-341.
106. Yuen MF, Lim WL, Chan AO, et al. Eighteen year follow-up study of a prospective randomized trial of hepatitis B vaccination without booster doses in children. *Clin Gastroenterol Hepatol*. 2004;2:941-945.
107. Floreani A, Baldo V, Cristofaletti M, et al. Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers. *Vaccine*. 2004;26:607-618.
108. Mendenhall M, Roselle GA, Lybecker LA, et al. Hepatitis B vaccination. Response of alcoholic with and without liver injury. *Dig Dis Sci*. 1988;33:263-269.
109. Rosman AS, Basu P, Glavin K, Lieber CS. Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: a randomized clinical trial. *Am J Med*. 1997;103:217-222.
110. Arslan M, Wiesner RH, Sievers C, et al. Double-dose accelerated hepatitis B vaccination in cirrhotic patients with end-stage liver disease. *Liver Transpl*. 2001;314-320.
111. Dominguez M, Barcena R, Garcia M, et al. Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list. *Liver Transpl*. 2000;6:440-442.
112. Keefe EB, Krause DS. Hepatitis B vaccination in patients with chronic liver disease. *Liver Transpl Surg*. 1998;4:437-439.
113. Wiedmann M, Liebert UG, Oesen U, et al. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. *Hepatology*. 2000;31:230-234.
114. Lee SD, Chan CY, Yu MI, et al. Hepatitis B vaccination in patients with chronic hepatitis C. *J Med Virol*. 1999;59:463-468.
115. Mattos AA, Gomes EB, Tovo CV, et al. Hepatitis B vaccine efficacy in patients with chronic liver disease by hepatitis C virus. *Arq Gastroenterol*. 2004;41:180-184.
116. Centers for Disease Control and Prevention. FDA approval for combined hepatitis A and B vaccine. *MMWR Morb Mortal Wkly Rep*. 2001;50:806-807.
117. Joines RW, Blattner M, Abraham B, et al. A prospective, randomized comparative U.S. trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Energix-B) in adults. *Vaccine*. 2001;19:4710-4719.
118. Centers for Disease Control and Prevention. 2009. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae, 2008. <http://www.cdc.gov/abcs/reports-findings/survreports/spneu08.html>. Accessed January 31, 2010.
119. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. *Cochrane Database Syst Rev*. 2008;1:CD000422.
120. Rehm S, Farley MM, File TM, et al. Higher pneumococcal disease vaccination rates needed to protect more at-risk US adults. *Postgrad Med*. 2009;121:101-105.
121. Weisfelt M, van de Beek D, Spanjaard L, et al. Clinical features, complications, and outcome in adults with pneumococcal meningitis: a prospective case series. *Lancet Neurology*. 2006;5:123-129.
122. Austrian R, Douglas RM, Schiffman G, et al. Prevention of pneumococcal pneumonia by vaccination. *Trans Assoc Am Physicians*. 1976;89:184-189.
123. Smit P, Oberholzer D, Hayden-Smith S, et al. Protective efficacy of pneumococcal polysaccharide vaccines. *JAMA*. 1977;238:2613-2616.
124. National Center for Health Statistics. Vaccination coverage estimates from the National Health Interview Survey: United States, 2008. Bethesda, MD: Centers for Disease Control and Prevention; 2009.
125. Kyaw M, Greene CM, Schaffner W, et al. Adults with invasive pneumococcal disease; missed opportunities for vaccination. *Am J Prev Med*. 2006;31:286-292.
126. Middleton DB, Lin CJ, Smith KJ, et al. Economic evaluation of standing order programs for pneumococcal vaccination of hospitalized elderly patients. *Infect Control Hosp Epidemiol*. 2008;29:385-394.

127. Skull SA, Andrews RM, Byrnes GB, et al. Missed opportunities to vaccinate a cohort of hospitalized elderly with pneumococcal and influenza vaccines. *Vaccine*. 2007;25:5146-5154.
128. Eckrode C, Church N, English WJ. Implementation and evaluation of a nursing assessment/standing orders-based inpatient pneumococcal vaccination program. *Am J Infect Control*. 2007;35:508-515.
129. Thomas CM, Loewen A, Coffin C, Campbell NRC. Improving rates of pneumococcal vaccination on discharge from a tertiary center medical teaching unit: a prospective intervention. *BMC Public Health*. 2005;5:110-116.
130. Centers for Medicare and Medicaid Services. Center for Medicaid and State Operations. Program memorandum: conditions of participation: immunization standards for hospitals, long-term care facilities, and home health agencies. Washington, DC: US Department of Health and Human Services, Centers for Medicare and Medicaid Services; 2002. Available at: <http://www.cms.hhs.gov/QuarterlyProviderUpdates/downloads/cms3160fc.pdf>. Accessed February 21, 2010.
131. Dexter PR, Perkins SM, Maharry KS, et al. Inpatient computer-based standing orders vs physician reminders to increase influenza and pneumococcal vaccination rates: a randomized trial. *JAMA*. 2004;292:2366-2371.
132. Coyle CM, Currie BP. Improving the rates of inpatient pneumococcal vaccination: impact of standing orders versus computerized reminders to physicians. *Infect Control Hosp Epidemiol*. 2004;25:904-907.
133. Centers for Disease Control and Prevention. Improving influenza, pneumococcal polysaccharide, and hepatitis B vaccination coverage among adults aged <65 years at high risk. *MMWR Recomm Rep*. 2005;54(RR-5):1-11.
134. Bourdet SV, Kelley M, Rublein J, Williams DM. Effect of a pharmacist-managed program of pneumococcal and influenza immunization on vaccination rates among adult inpatients. *Am J Health Syst Pharm*. 2003;60:1767-1771.
135. Sokos DR, Skledar SJ, Ervin KA, et al. Designing and implementing a hospital-based vaccine standing orders program. *Am J Health Syst Pharm*. 2007;64:1096-1102.
136. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. *JAMA* 2004;292:1333-1340.
137. Fiore AE, Shay DK, Broder K, et al. Prevention and control of seasonal influenza with vaccines. *MMWR Recomm Rep*. 2009;58(RR-8):1-52.
138. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. *JAMA*. 2003;289:179-186.
139. Nichol KL, Treanor JJ. Vaccines for seasonal and pandemic influenza. *J Infect Dis*. 2006;194:S111-S118.
140. Centers for Disease Control and Prevention. Estimated influenza vaccination coverage among adults and children-United States, September 1, 2004-January 31, 2005. *MMWR Morb Mortal Wkly Rep*. 2005;54:304-307.
141. Nichol KL, Wuorenma J, von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. *Arch Intern Med*. 1998;158:1769-1776.
142. Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. *JAMA*. 2000;284:1655-1663.
143. Jefferson TO, Rivetti D, DiPietrantonj C, et al. Vaccines for preventing influenza in healthy adults. *Cochrane Database Syst Rev*. 2007:CD001269.
144. Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. *N Engl J Med*. 1995;333:889-893.
145. Hak E, Buskens E, van Essen GA, et al. Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: the PRISMA study. *Arch Intern Med*. 2005;165:274-280.
146. Hak E, Buskens E, Nichol KL, et al. Do recommended high-risk adults benefit from a first influenza vaccination? *Vaccine*. 2006;24:2799-2802.
147. Looijmans-Van den Akker I, Verheij TJ, Buskens E, et al. Clinical effectiveness of first and repeat influenza vaccination in adult and elderly diabetic patients. *Diabetes Care*. 2006;29:1771-1776.
148. Huang KL, Ruben FL, Rinaldo CR, et al. Antibody responses after influenza and pneumococcal immunization in HIV-infected homosexual men. *JAMA*. 1987;257:2047-2050.
149. Govaert TM, Thijs CT, Masurel N, et al. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. *JAMA*. 1994;272:1661-1665.
150. Nichol KL, Nordin JD, Nelson DB, et al. Effectiveness of influenza vaccine in the community-dwelling elderly. *N Engl J Med*. 2007;357:1373-1381.
151. Bratzler DW, Houch PM, Jiang H, et al. Failure to vaccinate medicare inpatients. *Arch Intern Med*. 2002;162:2349-2356.
152. Berry BB, Ehler DA, Battiola RJ, et al. Influenza vaccination is safe and immunogenic when administered to hospitalized patients. *Vaccine*. 2001;19:3493-3498.